An International Multicenter Randomized Double-Blind Double-Dummy Parallel Group Study of 3-Month or 6-Month Treatment With SSR126517E [Idrabiotaparinux-sodium] (3.0 mg s.c. Once-Weekly) Versus Oral INR-Adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis.

Trial Profile

An International Multicenter Randomized Double-Blind Double-Dummy Parallel Group Study of 3-Month or 6-Month Treatment With SSR126517E [Idrabiotaparinux-sodium] (3.0 mg s.c. Once-Weekly) Versus Oral INR-Adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Idrabiotaparinux sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms CASSIOPEA
  • Most Recent Events

    • 28 Nov 2011 Primary endpoint 'Venous-thromboembolism-event-rate' has been met acording to results published in the Lancet
    • 28 Nov 2011 Results published in the Lancet.
    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top